Fragment-based drug discovery, also called as fragment-based lead recovery, is a measure to find lead compounds in drug discovery process. The process is based on identification of small chemical fragments that may not strongly bind to the biological target and combining or growing them in order to produce a lead that has higher similarity. The growing exploration of new drugs for the treatment of complex medical problems is the major factor leading to the increasing demand for fragment-based drug discovery market. Additionally, the market for fragment-based drug discovery has also resulted in domination of biopharmaceutical companies since the market is in need for a system that helps in discovery of lead compounds during the procedure of drug discovery.
The time-saving characteristics and prompt access to techniques related to biophysical fragment screening is the essential drivers of global fragment-based drug discovery market. The fragment-based drug discovery has emerged as a measure to design unique molecules. This system uses smaller ligands or fragments that consist of lower molecule weight. However, weak potency of some compounds which are the resultant of fragment screening and requirement of specific fragment libraries in order to conduct research are some of the key factors hindering the fragment-based drug discovery market growth.
Download Table of Content: https://www.acumenresearchandconsulting.com/tentative-table-of-content/468
The Fragment-based Drug Discovery Market is classified by services, end-user and geography. Based on services, the market is bifurcated into fragment optimization and fragment screening. The fragment screening market is sub-segmented into biophysical and non-biophysical techniques. Further, the biophysical techniques is segmented into isothermal titration calorimetry, fluorescence polarization, nuclear magnetic resonance spectroscopy, surface plasmon resonance, differential scanning fluorimetry, X-ray crystallography, mass spectrometry, biolayer interferometry, assay (thermal shift), capillary electrophoresis and others. The end-user segment of fragment-based drug discovery market is classified including contract research organizations (CROs), academic & research institutions and biopharmaceutical companies.
The geography segment includes North America, Asia-Pacific, Latin America, Europe and Middle East & Africa (MEA). North America is dominating the fragment-based drug discovery market and is anticipated to continue its dominance over coming years. The factors responsible for North America’s dominance include high investments by the key players in the research & development of the fragment-based drug discovery, advanced and developed infrastructure and healthcare systems in US and Canada. Also, the nations are often considered as the base for implementing technology advancements. The North America region is continuously focusing on development of techniques regarding fragment-based drug discovery by making use of outsourcing Asia-Pacific’s facilities. However, the demand in Asia-Pacific is growing at a very high pace in comparison to other regions, attributed to continuous investments in healthcare infrastructure and increasing focus in improving quality management particularly in China and Japan.
Request Customization: https://www.acumenresearchandconsulting.com/request-customization/468
Fragment-based drug discovery systems have developed considerably in popularity recently and have emerged as a great scope in the field of biopharmaceuticals. This consists of large companies, CROs and academic bodies. These systems have facilitated essentially in creating chemical series which have lead-like properties as these have enhanced the success rate of creation importantly than the conventional screening systems. Also, the fragment-based drug discovery systems have been proved to be extremely useful in marking out chemical series from multiple targets.
||Global Fragment-based Drug Discovery Market
||2014 – 2024
||2014 – 2015
||2017 – 2024
||Services, End-User, Geography
||North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)
||Market Trends, Drivers, Restraints, Porter’s Five Forces Analysis, Competitive Analysis, Player Profiling, Value Chain Analysis
The major players operating in the fragment-based drug discovery market include Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Charles River Laboratories International, Inc., Beactica AB, Emerald BioStructures, Inc., Crown Bioscience, Inc., Evotec AG, Proteros Fragments GmbH, Kinetic Discovery Limited, Sprint Bioscience, Sygnature Discovery and Structure Based Design, Inc. among others.
Inquiry Before Buying: https://www.acumenresearchandconsulting.com/inquiry-before-buying/468
Market By Services
o Biophysical techniques
§ Isothermal titration calorimetry
§ Fluorescence polarization
§ Nuclear magnetic resonance spectroscopy
§ Surface plasmon resonance
§ Differential scanning fluorimetry
§ X-ray crystallography
§ Mass spectrometry
§ Biolayer interferometry
§ Assay (thermal shift)
§ Capillary electrophoresis
o Non-biophysical techniques
Market By End-Users
Contract research organizations (CROs)
Academic & research institutions
Market By Geography
o Rest of Europe
o Rest of Asia-Pacific
o Rest of Latin America
Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o Rest of MEA
Buy Now This Report From Here: https://www.acumenresearchandconsulting.com/buy-now/0/468
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
Sales Manager | Acumen Research and Consulting
Ph – USA +1 716-2400-831